Telbivudine
- Generic Name
- Telbivudine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H14N2O5
- CAS Number
- 3424-98-4
- Unique Ingredient Identifier
- 2OC4HKD3SF
- Background
Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects.
- Indication
For the treatment of chronic hepatitis B in adult and adolescent patients ≥16 years of age with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
Randomized Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug in HBeAg Negative Chronic Hepatitis B Patients
- Conditions
- Interventions
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2015-06-16
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Registration Number
- NCT01260610
- Locations
- 🇮🇳
Institute of Liver & Biliary Sciences, New Delhi, India
Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy
- Conditions
- Interventions
- First Posted Date
- 2010-04-13
- Last Posted Date
- 2010-04-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT01102335
- Locations
- 🇨🇳
Liver cancer institute, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 27
- Registration Number
- NCT01005238
- Locations
- 🇨🇭
University Hospital, Basel, Switzerland
Study of Telbivudine in Chronic Hepatitis B
- Conditions
- First Posted Date
- 2009-09-02
- Last Posted Date
- 2016-02-29
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT00970216
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, LinKou, Taoyuan County, Taiwan
EFFicacy Optimization Research of Telbivudine Therapy
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 606
- Registration Number
- NCT00962533
- Locations
- 🇨🇳
West China Hospital.SiChuan University, ChengDu, Sichuan, China
🇨🇳Changhai Hospital affiliated to Second Military Medical University, ShangHai, Shanghai, China
🇨🇳302 Military Hospital of China, BeiJing, Beijing, China
Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission
- Conditions
- Interventions
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2009-10-14
- Lead Sponsor
- Southeast University, China
- Target Recruit Count
- 180
- Registration Number
- NCT00939068
Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection
- Conditions
- Interventions
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2008-12-18
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 600
- Registration Number
- NCT00810524
- Locations
- 🇨🇳
The Third Affiliated Hospital Of Sun Yat-sen University, Guangzhou, Guangdong, China
Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
- Conditions
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 83
- Registration Number
- NCT00805675
- Locations
- 🇨🇳
Department of Medicine, Queen Mary Hospital, Hong Kong, China
Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB)
- Conditions
- Interventions
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 15
- Registration Number
- NCT00804622
- Locations
- 🇨🇳
Department of Medicine, Queen Mary Hospital, Hong Kong, China
Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B
- First Posted Date
- 2008-10-28
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2200
- Registration Number
- NCT00781105
- Locations
- 🇨🇳
Novartis Investigative Site, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.